tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Sep 8;10(10)
fad457.
doi: 10.1093/ofid/ofad457. eCollection 2023 Oct. Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022
Ian D Plumb[SUP] 1 [/SUP], Nicholas M Mohr[SUP] 2 [/SUP], Melissa Hagen[SUP] 1 [/SUP], Ryan Wiegand[SUP] 1 [/SUP], Ghinwa Dumyati[SUP] 3 [/SUP], Karisa K Harland[SUP] 2 [/SUP], Anusha Krishnadasan[SUP] 4 [/SUP], Jade James Gist[SUP] 1 [/SUP], Glen Abedi[SUP] 1 [/SUP], Katherine E Fleming-Dutra[SUP] 1 [/SUP], Nora Chea[SUP] 5 [/SUP], Jane Lee[SUP] 6 [/SUP], Devra Barter[SUP] 7 [/SUP], Monica Brackney[SUP] 8 [/SUP], Scott K Fridkin[SUP] 9 [/SUP], Lucy E Wilson[SUP] 10 [/SUP], Sara A Lovett[SUP] 11 [/SUP], Valerie Ocampo[SUP] 12 [/SUP], Erin C Phipps[SUP] 13 [/SUP], Tiffanie M Marcus[SUP] 14 [/SUP], Howard A Smithline[SUP] 15 [/SUP], Peter C Hou[SUP] 16 [/SUP], Lilly C Lee[SUP] 17 [/SUP], Gregory J Moran[SUP] 18 [/SUP], Elizabeth Krebs[SUP] 19 [/SUP], Mark T Steele[SUP] 20 [/SUP], Stephen C Lim[SUP] 21 [/SUP], Walter A Schrading[SUP] 22 [/SUP], Brian Chinnock[SUP] 23 [/SUP], David G Beiser[SUP] 24 [/SUP], Brett Faine[SUP] 2 [/SUP], John P Haran[SUP] 25 [/SUP], Utsav Nandi[SUP] 26 [/SUP], Anne K Chipman[SUP] 27 [/SUP], Frank LoVecchio[SUP] 28 [/SUP], David A Talan[SUP] 18 [/SUP], Tamara Pilishvili[SUP] 1 [/SUP]
Affiliations
Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant.
Methods: We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates.
Results: Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants.
Conclusions: A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible.
Keywords: COVID-19; Omicron; SARS-CoV-2; healthcare personnel; vaccine effectiveness.
. 2023 Sep 8;10(10)
fad457.doi: 10.1093/ofid/ofad457. eCollection 2023 Oct. Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022
Ian D Plumb[SUP] 1 [/SUP], Nicholas M Mohr[SUP] 2 [/SUP], Melissa Hagen[SUP] 1 [/SUP], Ryan Wiegand[SUP] 1 [/SUP], Ghinwa Dumyati[SUP] 3 [/SUP], Karisa K Harland[SUP] 2 [/SUP], Anusha Krishnadasan[SUP] 4 [/SUP], Jade James Gist[SUP] 1 [/SUP], Glen Abedi[SUP] 1 [/SUP], Katherine E Fleming-Dutra[SUP] 1 [/SUP], Nora Chea[SUP] 5 [/SUP], Jane Lee[SUP] 6 [/SUP], Devra Barter[SUP] 7 [/SUP], Monica Brackney[SUP] 8 [/SUP], Scott K Fridkin[SUP] 9 [/SUP], Lucy E Wilson[SUP] 10 [/SUP], Sara A Lovett[SUP] 11 [/SUP], Valerie Ocampo[SUP] 12 [/SUP], Erin C Phipps[SUP] 13 [/SUP], Tiffanie M Marcus[SUP] 14 [/SUP], Howard A Smithline[SUP] 15 [/SUP], Peter C Hou[SUP] 16 [/SUP], Lilly C Lee[SUP] 17 [/SUP], Gregory J Moran[SUP] 18 [/SUP], Elizabeth Krebs[SUP] 19 [/SUP], Mark T Steele[SUP] 20 [/SUP], Stephen C Lim[SUP] 21 [/SUP], Walter A Schrading[SUP] 22 [/SUP], Brian Chinnock[SUP] 23 [/SUP], David G Beiser[SUP] 24 [/SUP], Brett Faine[SUP] 2 [/SUP], John P Haran[SUP] 25 [/SUP], Utsav Nandi[SUP] 26 [/SUP], Anne K Chipman[SUP] 27 [/SUP], Frank LoVecchio[SUP] 28 [/SUP], David A Talan[SUP] 18 [/SUP], Tamara Pilishvili[SUP] 1 [/SUP]
Affiliations
- PMID: 37799130
- PMCID: PMC10549208
- DOI: 10.1093/ofid/ofad457
Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant.
Methods: We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates.
Results: Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants.
Conclusions: A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible.
Keywords: COVID-19; Omicron; SARS-CoV-2; healthcare personnel; vaccine effectiveness.